NCT04093531View on ClinicalTrials.gov

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions
Primary Sjögren Syndrome
Interventions
DRUG

Ustekinumab

Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

University of Rochester

OTHER

NCT04093531 - Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome | Biotech Hunter | Biotech Hunter